Raymond James Weighs in on SolarCity (SCTY) Post Q4
Tweet
Share
E-mailGet Alerts SCTY Hot Sheet
Price: $0.01 --0%
Rating Summary:
4 Buy, 15 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
4 Buy, 15 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Raymond James analyst Pavel Molchanov reiterated his Market Perform rating and commented on SolarCity (NASDAQ: SCTY) following Q4 results.
Molchanov said, "While this textbook "story stock" has, in our view, become somewhat overheated, SolarCity is executing well - notwithstanding the (basically inconsequential) accounting glitch that delayed 4Q13 results. Its position as the top non-utility downstream pure-play in the U.S. market is secure, despite a competitive landscape that is getting tougher as vast amounts of capital flow to other lease providers as well. Balancing the impressive market position with a rich valuation, we maintain our Market Perform rating."
For an analyst ratings summary and ratings history on SolarCity click here. For more ratings news on SolarCity click here.
Shares of SolarCity closed at $77.10 yesterday.
Molchanov said, "While this textbook "story stock" has, in our view, become somewhat overheated, SolarCity is executing well - notwithstanding the (basically inconsequential) accounting glitch that delayed 4Q13 results. Its position as the top non-utility downstream pure-play in the U.S. market is secure, despite a competitive landscape that is getting tougher as vast amounts of capital flow to other lease providers as well. Balancing the impressive market position with a rich valuation, we maintain our Market Perform rating."
For an analyst ratings summary and ratings history on SolarCity click here. For more ratings news on SolarCity click here.
Shares of SolarCity closed at $77.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amazon.com (AMZN) PT Raised to $215 at UBS
- Sage Therapeutics (SAGE) PT Lowered to $18 at Truist Securities
- TechnipFMC (FTI) PT Raised to $30 at BTIG
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Raymond James, Pavel MolchanovSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
